191 related articles for article (PubMed ID: 23960085)
1. New oral anticoagulants in heart failure.
Van Gelder IC; Van Veldhuisen DJ; Lip GY
Eur J Heart Fail; 2013 Sep; 15(9):966-73. PubMed ID: 23960085
[No Abstract] [Full Text] [Related]
2. Dabigatran for stroke prevention in all patients with atrial fibrillation?
Hunchuck JE; Lake JD
Pharmacotherapy; 2011 Aug; 31(8):725-8. PubMed ID: 21923597
[No Abstract] [Full Text] [Related]
3. Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE-LY trial.
Ferreira J; Ezekowitz MD; Connolly SJ; Brueckmann M; Fraessdorf M; Reilly PA; Yusuf S; Wallentin L;
Eur J Heart Fail; 2013 Sep; 15(9):1053-61. PubMed ID: 23843099
[TBL] [Abstract][Full Text] [Related]
4. Dabigatran emerges as safe and effective warfarin alternative. The recently approved drug is more expensive, but appears to be more predictable.
Heart Advis; 2011 Jan; 14(1):4. PubMed ID: 22973590
[No Abstract] [Full Text] [Related]
5. Should the newer oral anticoagulants be withheld from patients with valvular AF?
Dalen JE
Chest; 2013 Aug; 144(2):369-370. PubMed ID: 23918100
[No Abstract] [Full Text] [Related]
6. Use of dabigatran to prevent stroke in patients with atrial fibrillation.
Mooney T
Nurs Stand; 2013 Mar 6-12; 27(27):35-41. PubMed ID: 23556305
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.
Chevalier J; Delaitre O; Hammès F; de Pouvourville G
Arch Cardiovasc Dis; 2014; 107(6-7):381-90. PubMed ID: 24973113
[TBL] [Abstract][Full Text] [Related]
8. Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin.
Zalesak M; Siu K; Francis K; Yu C; Alvrtsyan H; Rao Y; Walker D; Sander S; Miyasato G; Matchar D; Sanchez H
Circ Cardiovasc Qual Outcomes; 2013 Sep; 6(5):567-74. PubMed ID: 23922182
[TBL] [Abstract][Full Text] [Related]
9. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013.
Olesen JB; Sørensen R; Hansen ML; Lamberts M; Weeke P; Mikkelsen AP; Køber L; Gislason GH; Torp-Pedersen C; Fosbøl EL
Europace; 2015 Feb; 17(2):187-93. PubMed ID: 25236181
[TBL] [Abstract][Full Text] [Related]
10. An updated review of target-specific oral anticoagulants used in stroke prevention in atrial fibrillation, venous thromboembolic disease, and acute coronary syndromes.
Cove CL; Hylek EM
J Am Heart Assoc; 2013 Oct; 2(5):e000136. PubMed ID: 24152980
[No Abstract] [Full Text] [Related]
11. Dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
Berg AM
Ann Intern Med; 2011 Apr; 154(8):570; author reply 570-1. PubMed ID: 21502659
[No Abstract] [Full Text] [Related]
12. [Fewer strokes, lower mortality. Large general practice studies confirm good safety profile of dabigatran].
Einecke D
MMW Fortschr Med; 2014 Dec; 156(21-22):28, 30. PubMed ID: 25608388
[No Abstract] [Full Text] [Related]
13. Learning the respective roles of warfarin and dabigatran to prevent stroke in patients with nonvalvular atrial fibrillation.
Beyth RJ; Landefeld CS
Ann Intern Med; 2011 Nov; 155(10):714-5, W218. PubMed ID: 22084336
[No Abstract] [Full Text] [Related]
14. Dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
Edwards DB; Silverberg J
Ann Intern Med; 2011 Apr; 154(8):570; author reply 570-1. PubMed ID: 21502658
[No Abstract] [Full Text] [Related]
15. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion.
Nagarakanti R; Ezekowitz MD; Oldgren J; Yang S; Chernick M; Aikens TH; Flaker G; Brugada J; Kamensky G; Parekh A; Reilly PA; Yusuf S; Connolly SJ
Circulation; 2011 Jan; 123(2):131-6. PubMed ID: 21200007
[TBL] [Abstract][Full Text] [Related]
16. Atrial fibrillation in 2010: advances in treatment and management.
Connolly SJ
Nat Rev Cardiol; 2011 Feb; 8(2):67-8. PubMed ID: 21270842
[TBL] [Abstract][Full Text] [Related]
17. An anticoagulation option for nonvalvular atrial fibrillation.
Shaheen MH; Das P; Koshy SK; Jha SK; Kabra R
J Fam Pract; 2012 Jun; 61(6):E1-6. PubMed ID: 22670241
[No Abstract] [Full Text] [Related]
18. Efficacy and safety of dabigatran compared to warfarin in patients with paroxysmal, persistent, and permanent atrial fibrillation: results from the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) study.
Flaker G; Ezekowitz M; Yusuf S; Wallentin L; Noack H; Brueckmann M; Reilly P; Hohnloser SH; Connolly S
J Am Coll Cardiol; 2012 Feb; 59(9):854-5. PubMed ID: 22361407
[No Abstract] [Full Text] [Related]
19. Stroke prevention in nonvalvular atrial fibrillation.
Ganjehei L; Massumi A; Razavi M; Rasekh A
Tex Heart Inst J; 2011; 38(4):350-2. PubMed ID: 21841857
[No Abstract] [Full Text] [Related]
20. Use of novel oral anticoagulants for patients with atrial fibrillation: systematic review and clinical implications.
Albert NM
Heart Lung; 2014; 43(1):48-59. PubMed ID: 24373340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
